Dynavax Technologies (NASDAQ:DVAX) Announces Quarterly Earnings Results, Hits Estimates

Dynavax Technologies (NASDAQ:DVAX) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.05, Zacks reports. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%.

Dynavax Technologies Stock Performance

Shares of DVAX stock traded up $0.25 during midday trading on Thursday, hitting $13.34. The company had a trading volume of 1,866,594 shares, compared to its average volume of 1,802,517. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of 102.58 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $13.89. The company’s 50 day simple moving average is $12.80 and its 200 day simple moving average is $11.98.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. The Goldman Sachs Group cut shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. HC Wainwright upped their price objective on shares of Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, January 14th. Finally, StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.